Posted by Michael Wonder on 19 Jan 2023
Evaxion receives FDA fast track designation for personalised cancer immunotherapy
19 January 2023 - Evaxion Biotech today announced that the US FDA has granted fast track designation for the Company’s personalised cancer therapy, EVX-01, in combination with Keytruda.
In December 2022, Evaxion received FDA approval to proceed with its Phase 2b clinical trial, where EVX-01 is given in combination with Keytruda to patients with metastatic melanoma. On 17 January 2023, Evaxion furthermore received fast track designation for the vaccine candidate.
